GlassScriptPhysician profile
Kenneth Wenthen
NPI 1033592803
$5,542.35
in general payments reported to CMS, 2019-2025
29 companies · $1,194 in 2025
The $1,194 reported for 2025 was more than what 93% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $755 · 2020: $341 · 2021: $754 · 2022: $923 · 2023: $799 · 2024: $776 · 2025: $1,194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,770.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,769.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $972.70 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Alcon Vision LLC | $728.92 | 2019-2025 | Tryptyr, Hydrus Microstent, Simbrinza |
| Sun Pharmaceutical Industries INC. | $643.19 | 2019-2025 | Cequa |
| Aerie Pharmaceuticals, INC. | $492.57 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $288.50 | 2019-2021 | |
| Oyster Point Pharma, INC. | $280.88 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Glaukos Corporation | $263.11 | 2019-2024 | Istent Trabecular Micro-Bypass System Model Is3, Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3, Istent Infinite Trabecular Micro-Bypass System Model Is3 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $262.24 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $244.38 | 2020-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $180.85 | 2019-2023 | |
| Horizon Therapeutics Plc | $139.30 | 2019-2023 | Tepezza |
| Abbvie INC. | $138.89 | 2022-2025 | Alphagan P, Lumigan, Vuity |
| Tarsus Pharmaceuticals, INC. | $137.48 | 2024-2025 | Xdemvy |
| Amgen INC. | $120.25 | 2024 | Tepezza |
| Eyevance Pharmaceuticals LLC | $80.05 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $74.12 | 2019-2021 | |
| Astellas Pharma US INC | $65.39 | 2024 | Izervay |
| New World Medical,INC. | $61.02 | 2023 | |
| Biotissue Holdings INC. | $48.96 | 2025 | |
| Sight Sciences, INC. | $45.63 | 2020-2023 | Tearcare System |
| Johnson & Johnson Surgical Vision, INC. | $43.02 | 2025 | Tecnis Iol |
| Shire North American Group INC | $42.46 | 2019 | |
| Dompe US, INC. | $40.47 | 2021-2024 | Oxervate |
| Mallinckrodt Enterprises LLC | $37.89 | 2019 | |
| Thea Pharma INC. | $34.54 | 2023-2024 | Iyuzeh |
| Rxsight INC | $22.40 | 2025 | Rxsight Injector Cartridge, Rxsight Injector Handpiece, Rxsight Contact Lens |
| Ivantis, INC | $20.70 | 2021 | |
| Rayner Intraocular Lenses Limited | $18.73 | 2022 | |
| Optos, INC. | $13.71 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Wenthen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.